Bifeprunox in the Treatment of Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00193713
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- diagnosis of schizophrenia
- understand nature of study
- able to be managed in out-patient setting for long-term bifeprunox treatment
Exclusion Criteria
- current primary diagnosis other than schizophrenia
- suicide risk
- diagnosis or history of substance abuse
- uncontrolled hypertension
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method